Abstract
Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.
Original language | English (US) |
---|---|
Pages (from-to) | 793-798 |
Number of pages | 6 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 21 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2015 |
Externally published | Yes |
Keywords
- Monoclonal antibody
- Multiple myeloma salvage autologous stem cell transplant
- Relapsed/refractory
- Salvage allogenic stem cell transplant
ASJC Scopus subject areas
- Hematology
- Transplantation